Tech Company Financing Transactions
Regulus Therapeutics Funding Round
Regulus Therapeutics, based in San Diego, secured $20 million from Alnylam Pharmaceuticals and Ionis Pharmaceuticals.
Transaction Overview
Company Name
Announced On
3/4/2009
Transaction Type
Venture Equity
Amount
$20,000,000
Round
Series A
Investors
Alnylam Pharmaceuticals (John Maraganore)
Ionis Pharmaceuticals (Lynne Parshall)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
10614 Science Center Dr.
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
Regulus Therapeutics, Inc. (Nasdaq: RGLS), is a biopharmaceutical company created to discover, develop and commercialize microRNA-targeted therapeutics. microRNAs are small non-coding RNAs that regulate networks of genes and biological pathways through post-transcriptional mechanisms.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Joseph Hagan
Chief Financial Officer
Daniel Chevallard
VP - General Counsel
Christopher Aker
VP - R & D
Timothy Wright
Browse more venture capital transactions:
Prev: 3/4/2009: GetWellNetwork venture capital transaction
Next: 3/5/2009: Helix Therapeutics venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are sourced from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs